Recent studies have shown effective use of intravascular filtration devices to remove chemotherapy drugs; however, accurate quantification of the drug’s distribution on the device, within the targeted organ, and systemically, is necessary. We synthesized 18F analog of doxorubicin, fluorobenzylamide doxorubicin ([18F]FB-Dox), which was administered via an intra-arterial catheter, without a filter, and imaged under PET/MRI in vivo. [18F]FB-Dox showed a measurable decrease in the liver, and an increase in the bladder, kidney, and gall bladder over a 90-minute period after injection. This demonstrates a viable way to assess and track the baseline biodistribution of an intra-arterial chemotherapy procedure.
This abstract and the presentation materials are available to members only; a login is required.